MSCO
Macau Society of Clinical Oncology
  • Twitter
  • Facebook
  • Home
  • Home
  • Oncology News
  • CME & EDUCATION
  • Research
  • MSCO Activities
  • Membership
  • About us
WechatIMG75

Feb 21 2018

Monthly updates of NSCLC treatment and research from major journals: issue Feb 2018

This article summaries recent progresses published in high impact journals on lung cancer research and treatment. Kindly provided by Ms. Dandan Hu (胡丹丹), a MSI from Roche China, will continually update for every month. Article in Chinese.   Clinical Cancer Advances 2018: Annual Report on Progress Against  Cancer From the American Society of Clinical Oncology […]

Read More

By Yabing • Oncology News • 0

WechatIMG75

Feb 21 2018

Monthly updates of NSCLC treatment and research from major journals: issue Jan 2018

This article summaries recent progresses published in high impact journals on lung cancer research and treatment. Kindly provided by Ms. Dandan Hu (胡丹丹), a MSI from Roche China, will continually update for every month. Articles in Chinese. Immune-Related Adverse Events Associated with Immune Checkpoint  Blockade N Engl J Med 2018;378:158-68. 免疫检查点抑制剂在增强免疫系统活性的同时,也可能导致免疫副效应,通常被称作免疫相关不良事件。尽管任意器官均可能被累及,免疫相关不良事件最常发生在胃肠道,内分泌腺体,皮肤和肝脏,其次为中枢神经系统,心血管,肺,肌肉骨骼和血液系统。潜在广范围的免疫相关不良事件需要多学科协作处理。本篇综述聚焦了10个有关临床处理的基本问题并进行了解答,并提出了3个致力改善的机会。 10个基本问题: 1,       为什么会发生?精确的病理生理机制未知,转化研究提示T细胞、抗体、细胞因子反应可能参与了。 2,       […]

Read More

By Yabing • Oncology News • 0

Picture1

Jan 17 2018

Celebrating the first annul meeting of MSCO!

For the first time, MSCO brings together oncology professionals and research scientists from Macau, Hong Kong and Guangzhou to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. MSCO was established in 2016. The initial idea to establish this society, was in my mind in recent years. As a medical oncologist, and […]

Read More

By Yabing • MSCO Activities • 0

Jan 17 2018

Novel biomarker of lung adenocarcinoma in process of unsaturated fatty acid synthesis

Dr. Elaine Lai-Han Leung et al reported a new biomarker specifically and highly expressed in lung adenocarcinoma indicating poor prognosis.   The discovery of Warburg effect opens a new era in anti-cancer therapy. Aerobic glycolysis is regarded as a hallmark of cancer cells and increasing literatures indicates that metabolic changes are critical for the maintenance […]

Read More

By Yabing • Oncology News • 0

Dec 21 2017

Monthly updates of NSCLC treatment and research from major journals: issue Dec 2017

This article summaries recent progresses published in high impact journals on lung cancer research and treatment. Kindly provided by Ms. Dandan Hu (胡丹丹), a MSI from Roche China, will continually update for every month. Articles in Chinese. Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally  Advanced or Incompletely Resected Non–Small-Cell Lung Cancer. J Clin Oncol. 2017 […]

Read More

By Yabing • Oncology News • 0 • Tags: NSCLC

Screen Shot 2017-12-21 at 3.59.07 PM

Dec 21 2017

Novel Direct AMPK Activator Suppresses Non-Small Cell Lung Cancer through Inhibition of Lipid Metabolism

Dr Elaine Lai-Han Leung et al reported that a new AMPK agonist can specifically supress non-small cell lung cancer resistant cells viability by inhibition of lipid metabolism. Non-small cell lung cancer (NSCLC) dominates almost 85% of all lung cancer cases, becoming top 1 killer in the whole world. The patients whom harbor epidermal growth factor […]

Read More

By Yabing • Research • 0

Dec 4 2017

Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer

Journal of Thoracic Oncology (2017), doi: 10.1016/j.jtho.2017.10.011. 韩国三星医学中心回顾性分析,评估PD-1/PD-L1抑制剂是否会影响SCAI(salvage chemotherapy administered after immunotherapy,免疫治疗后的挽救性化疗)的疗效,将其与LCBI(last chemotherapy administered before immunotherapy,免疫治疗前的这线化疗)对比。共纳入73例分析,其中有10例接受了一线PD-1/PD-L1抑制剂治疗,63例LCBI 缓解数据可得。73例SCAI , 39例 (53.4%)缓解,而LCBI 缓解率为34.9% (22/63),p=0.03。根据含铂双药化疗、非含铂单药化疗进行分层,含铂双药化疗的缓解率在SCAI和LCBI分别为66.7%(16/24)和39.5%(17/43),p=0.03;非含铂单药化疗方案分别为 46.9% (23/49)和25.0%(5/20),p=0.09。结论:SCAI缓解率显著高于LCBI。这些数据提示抗PD-1/PD-L1抑制剂可能改善肿瘤对后续化疗的敏感性。

Read More

By Admin • Oncology News • 0

Dec 4 2017

Impact of Nivolumab Versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients With Advanced Squamous Non-Small Cell Lung Cancer: Results From the CheckMate 017 Study

Journal of Thoracic Oncology (2017), doi: 10.1016/j.jtho.2017.10.029. 欧美澳洲多中心、随机、开放标签Ⅲ期研究CheckMate 017的更新报道。本篇报道了健康相关生活质量和症状评估的结果。Nivolumab vs多西他赛,基线LCSS ASBI得分相似,均数29.6 vs 29.6。12周时,ASBI得分临床有意义改善比例为20.0% vs 21.9%。16-54周时,nivolumab组自基线ASBI得分显著改善 ;临床有意义改善出现在42-84周。未观察到多西他赛组有自基线的ASBI得分显著改善;36周时观察到有临床意义的恶化。其他方法评估结果支持nivolumab vs 多西他赛对HRQoL 的改善,至首次HRQoL 恶化的时间也更长。结论: Nivolumab对比多西他赛,可降低二线肺鳞癌治疗的症状负荷,改善健康状况。

Read More

By Admin • Oncology News • 0

Dec 4 2017

Randomized Phase III Trial of Low Molecular Weight Heparin Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: the RASTEN Trial

Annals of Oncology, mdx716, https://doi.org/10.1093/annonc/mdx716 Published: 02 November 2017 RASTEN,欧美多中心、随机、开放标签、Ⅲ期研究,低分子量肝素依诺肝素(LMWH)以超预防剂量(1 mg/kg)+标准治疗 vs 标准治疗应用新诊断的小细胞肺癌。阴性结果。在8年的时间内,研究共入组390例,LMWH组、对照组各186 、191例。首要终点OS无显著性差异,HR 1.11,P=0.36;PFS亦无差异, HR 1.18,P=0.14。对局限期、广泛期疾病的亚组分析未提示依诺肝素可以降低死亡。LMWH 组VTE(静脉血栓)发生率显著降低,HR 0.31,P=0.02;出血事件在LMWH组更常见,但致死性出血在两组相似。结论:在标准治疗的基础上联合低分子量肝素依诺肝素并不能改善小细胞肺癌患者的OS,不推荐临床按此常规应用。

Read More

By Admin • Oncology News • 0

Dec 4 2017

Letter to the editor

Nivolumab in non-small cell lung cancer with EGFR mutation Annals of Oncology, mdx745, https://doi.org/10.1093/annonc/mdx745 Published: 17 November 2017 日本京都大学附属医院单中心分析。24例EGFR突变非小细胞肺癌接受了nivolumab治疗,其中21例为常见EGFR突变(外显子19缺失或L858R点突变) 。部分缓解2例,RR 8%;4例疾病稳定,DCR 25%。单变量分析提示更高的BI (Brinkman Index,布林克曼指数≥600;为日均吸烟支数*吸烟年数)、更短的之前EGFR-TKI缓解持续时间(<6月),非常见EGFR突变与更长的PFS相关;多变量分析表明非常见EGFR突变是nivolumab疗效的独立预后因素。有3例患者PFS超过1年,其中2例高BI(均为1100),且对之前EGFR-TKI治疗的缓解持续时间较短(<3月);另1例从不吸烟,对之前EGFR-TKI治疗的缓解持续时间超过12个月,但有非常见突变G719X。这3例患者的PD-L1检测结果分别为<1%,≥50%和未知。 研究者推测可能是因为非常见突变和重度吸烟患者的肿瘤突变负荷更高,所以能从免疫治疗中获益。

Read More

By Admin • Oncology News • 0

«< 2 3 4 5 6 >»

Latest News

Latest News by MSCO

CME

Case Discussion

Event Calendar

Login

Register
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

↑

Copyright@MSCO. Macau Society of Clinical Oncology, 2017.